{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 451565314
| IUPAC_name = 2-(4-Chloro-2,5-dimethoxyphenyl)-''N''-[(2-methoxyphenyl)methyl]ethan-1-amine
| image = 2C-C-NBOMe-skeletal.svg
| image2 = 2C-C-NBOMe-spacefill.png

<!--Clinical data-->
| tradename = 
| legal_status =
| legal_DE = Anlage I
| legal_US =Schedule I
| legal_UK = Class A

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 1227608-02-7
| PubChem = 46856354
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24583389

<!--Chemical data-->
| C=18 | H=22 | Cl=1 | N=1 | O=3
| smiles = COc2ccccc2CNCCc(cc1OC)c(OC)cc1Cl
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H22ClNO3/c1-21-16-7-5-4-6-14(16)12-20-9-8-13-10-18(23-3)15(19)11-17(13)22-2/h4-7,10-11,20H,8-9,12H2,1-3H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = FJFPOGCVVLUYAQ-UHFFFAOYSA-N
}}

'''25C-NBOMe''' ('''NBOMe-2C-C''', '''2C-C-NBOMe''', '''Cimbi-82''') is a [[psychedelic drug]] and derivative of the psychedelic [[phenethylamine]] [[2C-C]]. 25C-NBOMe appeared on online vendor sites in 2010 but was not reported in the literature until 2011.<ref name="doi10.1007/s00259-010-1686-8">{{cite journal |doi=10.1007/s00259-010-1686-8 |last=Ettrup |first=A. |last2=Hansen |first2=M. |last3=Santini |first3=M. A. |last4=Paine |first4=J. |last5=Gillings |first5=N. |last6=Palner |first6=M. |last7=Lehel |first7=S. |last8=Herth |first8=M. M. |last9=Madsen |first9=J. |first10=J. |last10=Kristensen |displayauthors=9 |first11=M. |last11=Begtrup |first12=G. M. |last12=Knudsen |title=Radiosynthesis and ''in vivo'' evaluation of a series of substituted <sup>11</sup>C-phenethylamines as 5-HT<sub>2A</sub> agonist PET tracers |journal=European Journal of Nuclear Medicine and Molecular Imaging |volume=38 |issue=4 |pages=681–93 |year=2010 |pmid=21174090}}
</ref> It acts as a potent [[agonist]] for the [[5HT2A receptor|5HT<sub>2A</sub>]] [[Receptor (biochemistry)|receptor]],<ref>{{cite journal |last1=Hansen |first1=M. |last2=Phonekeo |first2=K. |last3=Paine |first3=J. S. |last4=Leth-Petersen |first4=S. |last5=Begtrup |first5=M. |last6=Bräuner-Osborne |first6=H. |last7=Kristensen |first7=J. L. |doi=10.1021/cn400216u |title=Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT<sub>2A/2C</sub> Agonists |journal=ACS Chemical Neuroscience |volume=5 |issue=3 |pages=243–9 |year=2014 |pmid=24397362|pmc=3963123
}}</ref> and has been studied in its [[Carbon-11|<sup>11</sup>C]] [[isotopic labelling|radiolabelled]] form as a potential ligand for mapping the distribution of 5-HT<sub>2A</sub> receptors in the brain, using [[positron emission tomography]] (PET).<ref name="doi10.1007/s00259-010-1686-8"/><ref>{{ cite web |url=http://bitnest.ca/external.php?id=%2518%253A3%25172%251BE%2524K%255BG%2521%2524%257D%2504%2504V |author =Hansen, M. |title=Design and Synthesis of Selective Serotonin Receptor Agonists for Positron Emission Tomography Imaging of the Brain |publisher=University of Copenhagen |year=2011 }}</ref>

==History==
25C-NBOMe is derived from the psychedelic phenethylamine [[2C-C]] by substitution on the amine with a 2-methoxybenzyl group. 25C-NBOMe is a clumpy white powder with a notably bitter and metallic taste. 25C-NBOMe has been found on blotter mimics sold as LSD.<ref>{{cite journal |last1=Zuba |first1=D. |last2=Sekuła |first2=K. |last3=Buczek |first3=A. |doi=10.1016/j.forsciint.2012.08.027 |title=25C-NBOMe – New potent hallucinogenic substance identified on the drug market |journal=Forensic Science International |volume=227 |issue=1–3 |pages=7–14 |year=2013 |pmid=22989597|pmc=}}</ref>

==Dosage==
[[File:25C-NBOMe blotter.jpg|thumb|Blotter paper containing 25C-NBOMe]]
Anecdotal reports from human users suggest 25C-NBOMe to be an active hallucinogen at a dose of as little as 200-500 [[microgram|µg]] insufflated and 300-600&nbsp;µg buccaly (with threshold doses even lower), making it only half to a third the potency of [[LSD]].<ref>[http://www.erowid.org/chemicals/2cc_nbome/2cc_nbome_dose.shtml 2C-C-NBOMe Dose] - [[erowid]]</ref> NBOMe-substituted compounds have a diminished absorption rate passing through mucus membranes, but generally remain inactive when taken orally. [[Buccal administration|Buccal]], [[sublingual]] or [[insufflation (medicine)|insufflated]] routes of administration are all viable options. Absorption rate [[Buccal administration|buccally]] and [[sublingually]] can be increased when complexed with [[HPBCD]] complexing sugar, however the most efficient is [[nasal administration]], which shortens the duration while increasing intensity, but has been attributed to several overdoses due to improper dosing.<ref name="Grautoff_2014"/>

== Effects ==

{{col-begin}}
{{col-break}}

=== Desired ===
* strong open- and closed-eye [[hallucination|visuals]], including trails, color shifts, brightening, etc.
* mood lift
* [[euphoria]]
* mental and physical [[stimulation]]
* increase in associative & creative thinking
* increased awareness & appreciation of music
* life-changing spiritual experiences
* feelings of [[love]] and [[empathy]]
* increased [[pattern recognition (psychology)]]
* [[synesthesia]] and [[chromesthesia]] (intensified for those who experience these while sober)
{{col-break}}

=== Neutral ===
* general change in [[consciousness]]
* [[mydriasis|pupil dilation]]
* unusual body sensations ([[paresthesia]], [[flushing (physiology)|flushing]], [[chills]], [[goose bumps]])
* change in perception of time, time dilation
* [[tachycardia|increased]] heart rate
* jaw clenching ([[bruxism]])
* [[yawning]], especially when coming up
* [[insomnia]]
* looping, [[recursion|recursive]], out-of-control thinking
* [[Dissociative|dissociation]]
{{col-break}}

=== Undesired ===
(Includes negative side effects arising from overdose; likelihood of negative side effects increases with dose)
* [[confusion]] and difficulty focusing
* scrambled communication
* tunnel vision
* [[vasoconstriction]]
* [[nausea]] and vomiting (normally only during the onset for those affected)
* [[paranoia]], [[fear]], and [[panic]]
* irritation of the throat
* irritation of mucous membranes
* upper respiratory irritation and difficulty breathing/swallowing
* unwanted and overwhelming feelings or life-changing spiritual experiences
* [[Syncope (medicine)|syncope]]
* [[tremor|shaking]]
* [[dystonia]], [[clonus]] and [[seizure]]
* [[death]]
{{col-end}}

== Toxicity and harm potential ==

25C-NBOMe overdoses have been linked to multi-organ failure.<ref name="Grautoff_2014">{{cite journal |url=https://link.springer.com/article/10.1007%2Fs00063-014-0360-5 |title=Lebensgefährliche Intoxikation mit der neuen psychoaktiven Substanz 25C-NBOMe |author1=S. Grautoff |author2=J. Kähler |journal=Medizinische Klinik - Intensivmedizin und Notfallmedizin |date=May 2014 |volume=109 |issue=4 |pages=271–275 |doi=10.1007/s00063-014-0360-5 |pmid=24770890 |language=German}}</ref><ref>{{cite journal |url=http://ugeskriftet.dk/videnskab/fatalt-forloeb-efter-intoksikation-med-det-nye-designerdrug-25c-nbome |title=Fatalt forløb efter intoksikation med det nye designerdrug 25C-NBOMe |vauthors=Tarpgaard M, Mærkedahl R, Lauridsen KB |journal=Ugeskrift for Laeger |date=August 2015 |pmid=26324189 |language=Danish |volume=177|issue=35 }}</ref>

==Drug prohibition laws==

===Canada===
As of October 31, 2016; 25C-NBOMe is a controlled substance (Schedule III) in Canada. http://gazette.gc.ca/rp-pr/p2/2016/2016-05-04/html/sor-dors72-eng.php

=== Israel ===
The NBOMe series of psychoactives became controlled in Israel in May, 2013.<ref name="erowid-law" /><ref>{{cite web |url=http://www.health.gov.il/English/Pages/HomePage.aspx |title=Amendment to Dangerous Drugs Ordinance |work=Israeli Ministry of Health |date=7 June 2013 |accessdate=11 September 2015}}</ref>

=== New Zealand ===
25C-NBOMe was sold as a [[designer drug]] in New Zealand in early 2012, but was withdrawn from sale after a statement by Associate Health Minister Peter Dunne that 25C-NBOMe would be considered to be substantially similar in chemical structure to the illegal hallucinogen [[2,5-Dimethoxy-4-bromoamphetamine|DOB]], and was therefore a Class C controlled drug analogue.<ref>[http://www.sciencemediacentre.co.nz/2012/03/13/legal-high-dime-not-so-legal/ ‘Legal high’ DIME not so legal. Science Media Centre, March 13th 2012]</ref>

=== Russia ===
Russia became the first country to regulate the NBOME class. The entire NBOMe series of psychoactives became controlled in the Russian Federation starting October, 2011.<ref name="erowid-law">{{cite web |url=https://www.erowid.org/chemicals/nbome/nbome_law.shtml |title=NBOMe Series Legal Status |publisher=Erowid |accessdate=5 September 2015}}</ref><ref>{{cite web |url=http://www.rg.ru/2011/10/19/narko-dok.html |title=Постановление Правительства Российской Федерации от 6 октября 2011 г. N 822 г. Москва |date=19 October 2011 |accessdate=5 September 2015 |language=Russian}}</ref>

=== Sweden ===
[[Riksdag|''Sveriges riksdag'']] added 25C-NBOMe to schedule I (''"substances, plant materials and fungi which normally do not have medical use"'') as narcotics in Sweden as of Aug 1, 2013, published by [[Medical Products Agency (Sweden)|''Medical Products Agency'']] in their regulation '''LVFS 2013:15''' listed as '''25C-NBOMe 2-(4-kloro-2,5-dimetoxifenyl)-N-(2-metoxibensyl)etanamin'''.<ref>{{cite web |url=https://lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf |title=Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika |date=24 July 2013 |accessdate=5 September 2015 |author =Generaldirektör Ch ristina Rångemark Åkerman}}</ref>

=== United Kingdom ===
{{N-benzylphenethylamine-Legality-United Kingdom}}

=== United States ===
Several NBOMe series compounds will be temporarily scheduled in the United States for 2 years. The temporary scheduling applies to 25C-NBOMe, 25B-NBOMe, and 25I-NBOMe.<ref>{{cite web |url=http://www.gpo.gov/fdsys/pkg/FR-2013-10-10/pdf/2013-24432.pdf |title=Proposed Rules |publisher=Drug Enforcement Administration (DEA) |date=10 October 2013 |accessdate=5 September 2015 |author =Thomas M. Harrigan}}</ref> In November 2015, the temporary scheduling was extended for another year.<ref name=pmid26567439>{{cite journal | journal = Fed Regist. | date = 2015 | volume = 80 | issue = 219 | pages = 70657–9 | title = Schedules of Controlled Substances: Extension of Temporary Placement of Three Synthetic Phenethylamines in Schedule I. Final order | author = Drug Enforcement Administration | pmid= 26567439}}</ref>

=== China ===
As of October 2015 25C-NBOMe is a controlled substance in China.<ref>{{cite web | url=http://www.sfda.gov.cn/WS01/CL0056/130753.html | title=关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | publisher=China Food and Drug Administration | date=27 September 2015 | language=Chinese | accessdate=1 October 2015}}</ref>

=== Czech Republic ===
25C-NBOMe is banned in the Czech Republic.<ref>{{cite web | url=http://www.mzcr.cz/Admin/_upload/files/3/Nov%C3%A9%20PL.pdf | title=Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení vlády č. 463/2013 Sb.) | publisher=Ministerstvo zdravotnictví | language=Czech}}</ref>

==Analogues and derivatives==
{{2C-C analogues and derivatives}}

==References==
{{reflist}}

{{Hallucinogens}}
{{Serotonin receptor modulators}}
{{Phenethylamines}}

[[Category:25-NB (psychedelics)]]
[[Category:Chloroarenes]]
[[Category:Phenol ethers]]
[[Category:Designer drugs]]